ClinicalTrials.gg
CompletedNCT01938612Updated Mar 12, 2021

A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours

A Phase 1 interventional study of MEDI4736 and tremelimumab in Advanced Solid Tumors, sponsored by AstraZeneca. Completed at 21 sites in 3 countries. Open to participants aged 20 Years to 130 Years. Per ClinicalTrials.gov, last updated 2021-03-12.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
269
Allocation
Non-randomized
Ages
20 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing durvalumab in Squamous Cell Carcinoma of Head and Neck — none open to participants now, 3 under way, none of them phase 3. durvalumab · Squamous Cell Carcinoma of Head and Neck.

Enrollment
2nd of 20
269 · median 40
Started
2013
the only one that year
Phase 1
7 of 20
none open now
Registered
1st of 20
by date
Lead sponsor
4 of 20
AstraZeneca

Among the 20 studies testing durvalumab in Squamous Cell Carcinoma of Head and Neck, this one is the 2nd largest by enrollment, is the only one that started in 2013, is one of 7 in phase 1, and was the 1st registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

None of the 20 studies testing durvalumab in Squamous Cell Carcinoma of Head and Neck is open now. The open studies under Squamous Cell Carcinoma of Head and Neck, anywhere →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 20 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies testing durvalumab in Squamous Cell Carcinoma of Head and Neck as a file.
02

Study summary

This is a phase I, open-label, multicentre study of MEDI4736 administered intravenously with a standard 3+3 dose-escalation phase to evaluate safety, tolerability, and pharmacokinetics in patients with advanced solid tumor followed by an expansion phase in patients with advanced solid tumors.

03

Conditions studied

  • Advanced Solid Tumors

Keywords

  • MEDI4736
  • Advanced solid tumors
  • squamous cell carcinoma of the head and Neck
  • biliary tract cancer
  • squamous cell carcinoma of esophagus cancer
  • B7-H1
  • PD-L1
04

Who can participate

Ages eligible
20 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • In the dose-escalation phase: patients with advanced solid tumors to standard treatment, intolerant of standard treatment, or for which no standard therapy exists.

In the dose-expansion phase: - or cytologically-confirmed advanced or biliary tract cancer (BTC), esophagus cancer(EC) (squamous cell carcinoma) or squamous cell carcinoma of the head and neck (SCCHN). - men or women. - (ECOG) status of 0 or 1. - Adequate organ and marrow function. - Subjects must have at least 1 . - Available archived tumor tissue sample. - Willingness to provide consent for samples.

Exclusion criteria

Exclusion Criteria:

  • Any prior Grade ≥ 3 irAE while receiving immunotherapy - Prior exposure to any or anti-PD-L1 antibody - Active or prior documented disease within the past 2 years - History of primary immunodeficiency - Symptomatic or untreated central nervous system (CNS) requiring concurrent treatment - Women who are pregnant or lactating - Uncontrolled intercurrent illness - Known history of tuberculosis - Known to be (HIV) positive - or C infection - Other invasive within 5 years
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
269 participants (actual)

Study arms

  • Experimental
    MEDI4736 Q2W

    Evaluate MEDI4736 given every 2 weeks

    Drug: MEDI4736

  • Experimental
    MEDI4736 Q3W

    Evaluate MEDI4736 given every 3 weeks

    Drug: MEDI4736

  • Experimental
    MEDI4736 Dose Expansion

    evaluate MEDI4736 given every 2 weeks

    Drug: MEDI4736

  • Experimental
    MEDI4736 Q4W

    Evaluate MEDI4736 given every 4 weeks

    Drug: MEDI4736

  • Experimental
    MEDI4736 combined with another drug

    evaluate MEDI4736 in combination with another drug given every 4 weeks

    Drug: tremelimumab

Interventions

  • MEDI4736 will be administered by IV infusion every 14, 21 or 28 days.

  • tremelimumab is administered by IV infusion every 4 weeks

06

What researchers measure

Primary outcomes

  1. Number of participants experiencing dose-limiting toxicities, adverse events (AEs), serious adverse events (SAEs)

    Safety profile will be assessed through number of participants experiencing adverse events (AEs), serious adverse events (SAEs), laboratory evaluations, vital signs, and physical examinations.

    Time frame: 90 days after the last dose of MEDI4736

Secondary outcomes

  1. Area under the concentration of MEDI4736 time curve

    If data allow, noncompartmental PK parameter (AUC) will be estimated.

    Time frame: Up to 90 days after the last dose of MEDI4736

  2. Percentage of participants who developed detectable anti-drug antibodies (ADAs).

    The immunogenic potential of MEDI4736 or tremelimumab will be assessed by summarizing the number percentage of subjects who develop detectable anti-drug antibodies (ADAs).

    Time frame: Up to 6 months after the last dose of MEDI4736 or up to 1 month after the last dose of tremelimumab where applicable.

  3. Objective response rate (ORR)

    Time frame: From first dose of study drug until death or up to 2 years

  4. Maximum tolerated dose (MTD) or optimal biological dose (OBD)

    maximum tolerated dose (MTD) or optimal biological dose (OBD) of MEDI4736, if possible

    Time frame: 90 days after the last dose of MEDI4736

  5. Maximum concentration of MEDI4736

    If data allow, noncompartmental PK parameter (Cmax) will be estimated.

    Time frame: Up to 90 days after the last dose of MEDI4736

  6. Clearance

    If data allow, noncompartmental PK parameter (CL) will be estimated.

    Time frame: Up to 90 days after the last dose of MEDI4736

  7. half-life after administration of MEDI4736

    If data allow, noncompartmental PK parameter (t½) will be estimated.

    Time frame: Up to 90 days after the last dose of MEDI4736

  8. Disease control rate (DCR)

    Time frame: From first dose of study drug until death or up to 2 years

  9. Duration of response (DoR)

    Time frame: From first dose of study drug until death or up to 2 years

  10. Progression-free survival (PFS)

    Alive and progression free at 6 months (APF6) and 12 months (APF12) will be obtained using the Kaplan-Meier plot of PFS.

    Time frame: From first dose of study drug until death or up to 2 years

  11. Overall survival (OS)

    The proportion of patients alive at 12 months will be obtained from the Kaplan-Meier plot of OS.

    Time frame: From first dose of study drug until death or up to 2 years

07

Study locations

21 sites
  • Research Site
    Beppu-shi, 874-0011, Japan
  • Research Site
    Chuo-ku, 104-0045, Japan
  • Research Site
    Kashiwa, 277-8577, Japan
  • Research Site
    Kitaadachi-gun, 362-0806, Japan
  • Research Site
    Koto-ku, 135-8550, Japan
  • Research Site
    Kure-shi, 737-0023, Japan
  • Research Site
    Matsuyama-shi, 791-0280, Japan
  • Research Site
    Nagoya-shi, 464-8681, Japan
  • Research Site
    Osaka-shi, 541-8567, Japan
  • Research Site
    Osakasayama, 589-8511, Japan
  • Research Site
    Sapporo-shi, 003-0804, Japan
  • Research Site
    Sapporo-shi, 060-8648, Japan
  • Research Site
    Suita-shi, 565-0871, Japan
  • Research Site
    Sunto-gun, 411-8777, Japan
  • Research Site
    Takatsuki-shi, 569-8686, Japan
  • Research Site
    Yokohama-shi, 241-8515, Japan
  • Research Site
    Seoul, 03080, Korea, Republic of
  • Research Site
    Seoul, 135-710, Korea, Republic of
  • Research Site
    Tainan, 704, Taiwan
  • Research Site
    Taipei, 10002, Taiwan
  • Research Site
    Taoyuan, 333, Taiwan
08

References and documents

Publications

  • Doki Y, Ueno M, Hsu CH, Oh DY, Park K, Yamamoto N, Ioka T, Hara H, Hayama M, Nii M, Komuro K, Sugimoto M, Tahara M. Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer. Cancer Med. 2022 Jul;11(13):2550-2560. doi: 10.1002/cam4.4593. Epub 2022 May 24. PubMed 35611499 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2013 to primary completion in Mar 2018, 53 months.

Of 154 industry-sponsored phase 1 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 72. This study's 53 months is close to that.

Counting every sponsor, half of 270 studies reached it within 49 months; a quarter within 33 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2013
First posted
Sep 10, 2013
StartActual
Sep 12, 2013
Primary completionActual
Mar 1, 2018
CompletionActual
Nov 25, 2020
Last update
Mar 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01938612
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 10, 2013
Start date
Sep 12, 2013
Primary completion
Mar 1, 2018
Completion
Nov 25, 2020
Last update
Mar 12, 2021

Study contacts

Robert Iannone, MD
study director · AstraZeneca

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Durvalumab · Tremelimumab

Start the discussion